Journal
BRITISH JOURNAL OF CANCER
Volume 122, Issue 11, Pages 1580-1589Publisher
SPRINGERNATURE
DOI: 10.1038/s41416-020-0814-x
Keywords
-
Categories
Funding
- Intramural Research Program of the NIH, NCI
- NATIONAL CANCER INSTITUTE [ZIABC011640, ZIABC011707, ZIABC011684, ZIABC011647, ZIABC011643, ZIABC011761, ZIABC011710, ZIDBC011642, ZIABC011714] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Isocitrate dehydrogenase (IDH) enzymes catalyse the oxidative decarboxylation of isocitrate and therefore play key roles in the Krebs cycle and cellular homoeostasis. Major advances in cancer genetics over the past decade have revealed that the genes encoding IDHs are frequently mutated in a variety of human malignancies, including gliomas, acute myeloid leukaemia, cholangiocarcinoma, chondrosarcoma and thyroid carcinoma. A series of seminal studies further elucidated the biological impact of the IDH mutation and uncovered the potential role of IDH mutants in oncogenesis. Notably, the neomorphic activity of the IDH mutants establishes distinctive patterns in cancer metabolism, epigenetic shift and therapy resistance. Novel molecular targeting approaches have been developed to improve the efficacy of therapeutics against IDH-mutated cancers. Here we provide an overview of the latest findings in IDH-mutated human malignancies, with a focus on glioma, discussing unique biological signatures and proceedings in translational research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available